| March 6, 2014 | ISSUE NUMBER 341 VOL 3 |
Special Feature
Pharm Exec’s Annual Industry Audit 2014
Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years ...Read more
Drug Safety
Track-and-Trace Not Enough to Halt Drug Counterfeiters
Despite recent legislation to establish a more secure pharmaceutical supply chain to deliver high quality, approved medicines to American patients, efforts to block the import of substandard, fraudulent and counterfeit drugs remains an uphill fight, writes Jill Wechsler
...Read more
White Paper – Reprints at the Dawn of the 'Sunshine Act'
Medical journal article reprints provide health care professionals credible clinical evidence that a product works. Read about the new reprint regulations emerging from the Physician Payment Sunshine Act. Learn about newer ePrint formats and discover new distribution channels to get the right article to the right prescriber at the right time.
 Read more
Leadership
Pharm Exec’s Emerging Pharma Leaders 2014 — Nominate Now
It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself. ...Read more
Europe
Whatever Happened to Faster Pricing and Reimbursement for Generics?
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes EU correspondent Reflector ...Read more
Profile
Pushing the Boundaries of MS Research: The Myelin Foundation
The Myelin Repair Foundation is more than just a policy precedent — it’s also emerging as the stimulus behind a future cure for MS. William Looney reports ...Read more
eBook
Pharmaceutical Executive’s Digital Marketing Three eBook & Video Combo
Pharmaceutical Executive brings you the perfect combination of resources to increase your digital marketing IQ: an eBook with 10 must-read topics and more than four hours of in-depth video presentations by marketing experts Augustine Fou, Mike Moran and Mark Schaefer ...Read more |
|
|
|
 //Accele Biopharma, Inc. (Oklahoma City, OK) has assumed the management of Synereca Pharmaceuticals, Inc. Clayton I. Duncan, Accele’s Chairman and Chief Executive Officer, will serve as Chairman and Chief Executive Officer of Synereca.//Celladon Corporation (San Diego, CA) announced it has appointed Dr. Peter K. Honig and Dr. Patrick Y. Yang to its Board of Directors.//Vansen Pharma Inc. (Las Vegas, NV), appointed Dr. Ahmad Doroudian as President and Chief Executive Officer.//Mark P. Carthy joined the Board of Directors of Rexahn Pharmaceuticals, Inc. (Rockville, MD).//Synta Pharmaceuticals Corp. (Lexington, MA) announced that Safi R. Bahcall, Ph.D., resigned as President, Chief Executive Officer and member of the Board of Directors, and has been replaced by a newly formed Executive Committee of the Board, chaired by Keith R. Gollust and including Robert N. Wilson and Paul A. Friedman, M.D.// |
|
|
|
|
|
